Skip to main content

Table 1 Demographic and clinical data of Chronic Hepatitis B (CHB)-associated Acute-on-Chronic Liver Failure (ACLF) patients (N = 12), treatment naive CHB patients (NA = 27)

From: Chronic hepatitis B carriers with acute on chronic liver failure show increased HBV surface gene mutations, including immune escape variants

 

CHB-ACLF (HBeAg positive, N = 6)

CHB-ACLF (HBeAg negative, N = 6)

Treatment naïve CHB

Immune tolerance (N = 2)

Immune active (N = 9)

Inactive (N = 5)

HBeAg negative hepatitis (N = 11)

Median age (range)/# male

49 (21–64)/6

52 (26–57)/5

28 (20–35)/1

47 (23–50)/2

52 (45–61)/1

43 (36–57)/11

Ethnicity

6 Chinese

6 Chinese

1 Chinese; 1 Eastern European

6 Chinese; 1 Tibetian; 1 Vietnam; 1 Indonesia

3 East- Europe; 1 Korean; 1 African

6 Chinese; 1 Lebanese; 2 Vietnam; 1 Fillipino; 1 Egyptian

Median HBV DNA (rang, log IU/mL)

5.7 (4.3–7.3)

3.7 (2.2–5.9)

8.5 (8.0–8.6)

8.0 (4.5–9.0)

3.1 (UD-3.6)

4.3 (2.9–6.2)

Median ALT (rang, U/L)

562 (23–1584)

112 (48–2347)

37 (20–33)

86 (27–353)

25 (14–48)

48 (20–106)

# HBeAg negative patients

0/6

6/6

0/2

0/9

5/5

11/11

Genotype

1 B; 3 C; 2 unknown

2 B; 2 C; 2 unknown

1 B, 1 D

3 B, 5 C, 1 D

1 A, 1 B, 1 C, 1 D, 1 E

4 B, 4 C, 2 D, 1E

Median HBsAg (rang, log IU/mL3)

unknown

unknown

unknown

4.0 (2–9.8)

3.9 (2.7–5.1)

3.5 (1.6–9.1)

# Liver fibrosis

3/6

5/6

0/2

3/9

0/5

5/11

# History of NA treatment

1 LAM

4 LAM

N/A

NA

N/A

NA

# Surviral (4 weeks after onset)

2/6

2/6

All alive

All alive

All alive

All alive

  1. UD undetectable